European Psychiatry (Mar 2023)

Bipolar Disorder and Parkinson disease: a 123I-FP-CIT SPECT study

  • G. D’agostino,
  • G. Cascino,
  • A. M. Landolfi,
  • R. Erro,
  • P. Barone,
  • P. Monteleone

DOI
https://doi.org/10.1192/j.eurpsy.2023.1090
Journal volume & issue
Vol. 66
pp. S513 – S513

Abstract

Read online

Introduction Bipolar Disorder (BD) has been suggested to be a risk factor for development of Parkinson Disease. Psychiatric drugs used as standard treatment of BD includes many drugs that are known to induce drug-induced parkinsonism (DIP). Objectives Clinical differentiation between PD and DIP is a clinical and scientific crucial result. It might be aided by functional neuroimaging of the dopaminergic nigrostriatal pathway. Methods Twenty consecutive BD patients with parkinsonism were clinically assessed and underwent 123I-ioflupane dopamine transporter SPECT. Imaging data of BD patients with pathological nigrostriatal pathway were further compared to a population of de-novo PD patients. Results Four BD patients had abnormal scans; they had higher putaminal binding ratio and putamen-to-caudate ratios than PD patients, despite similar motor symptom burden. Conclusions in our initial results, up to 20% of BD patients with parkinsonism might have an underlying dopaminergic deficit, which is higher than excepted in the general population. This evidences supports that BD represents a risk factor for subsequent development of neurodegenerative parkinsonism. Disclosure of Interest None Declared